
Brief intro:
- Author: Shuai Lu, Xi-xiu Xie,Lei Zhao, Bin Wang, Jie Zhu, Ting-rui Yang, Guang-wen Yang, Mei Ji, Cui-ping Lv, Jian Xue, Er-hei Dai, Xi-ming Fu, Dong-qun Liu, Lun Zhang, Sheng-jie Hou, Xiao-lin Yu, Yu-ling Wang, Hui-xia Gao, Xue-han Shi, Chang-wen Ke, Bi-xia Ke, Chun-guo Jiang, and Rui-tian Liu
- Journal: Cell Reports
- Doi: https://www.doi.org/10.1016/j.celrep.2020.108666
- Publication Date: 2021 Jan 26
Products/Services used in the paper
Quotation shows PackGene:D614 SARS-CoV-2 pseudoviruses (Cat#LV-nCov1); G614 SARS-CoV-2 pseudoviruses (Cat#LV-nCov1); ACE2-239T cells (Cat#nCov-3)
Research Field:Covid-related
Abstract
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are under development, the antigen epitopes on the virus and their immunogenicity are poorly understood. Here, we simulate the 3D structures and predict the B cell epitopes on the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 using structure-based approaches and validate epitope immunogenicity by immunizing mice. Almost all 33 predicted epitopes effectively induce antibody production, six of these are immunodominant epitopes in individuals, and 23 are conserved within SARS-CoV-2, SARS-CoV, and bat coronavirus RaTG13. We find that the immunodominant epitopes of individuals with domestic (China) SARS-CoV-2 are different from those of individuals with imported (Europe) SARS-CoV-2, which may be caused by mutations on the S (G614D) and N proteins. Importantly, we find several epitopes on the S protein that elicit neutralizing antibodies against D614 and G614 SARS-CoV-2, which can contribute to vaccine design against coronaviruses.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
